Flamel secures $4M from Glaxo for cardiovascular product line

Justine Varieur Cadet | | Cardiovascular Business | Structural Heart Disease
Flamel Technologies has earned an additional $4 million milestone from GlaxoSmithKline (GSK) pursuant to its Micropump license agreement for Coreg CR (carvedilol phosphate extended release capsules).

The Lyon, France-based Flamel said its Coreg CR was launched by the London-based GSK in 2007 and is indicated for use in treating three cardiovascular conditions:
  • Hypertension;
  • Post-MI left ventricular dysfunction; and
  • Mild to severe heart failure.

The company said its Coreg CR microparticles are produced by Flamel Technologies at its production facility in Pessac, France, using its Micropump technology platform,

"Flamel is engaged in 18 feasibility study programs with seven of the top twenty pharmaceutical companies," said Stephen H. Willard, Flamel's CEO.

Justine Varieur Cadet

Related Content

New TAVR research explores adverse outcomes, disease progression in patients with asymptomatic severe AS
Dapagliflozin improves outcomes for elderly TAVR patients with heart failure
Bringing state-of-the-art healthcare to Florida heart patients
Cardiologists make case against routine interventions for asymptomatic severe AS
First comprehensive T-TEER resource examines best practices for tricuspid valve repair
So far, so good: TAVR comparable to open heart surgery after 5 years in low-risk patients

Around the web

Radiology Business
The impact of Trump tariffs on iodine contrast media costs

GE HealthCare said the price of iodine contrast increased by more than 200% between 2017 to 2023. Will new Chinese tariffs drive costs even higher?

Radiology Business
Key takeaways from RSNA 2024 for AI, CT, MRI and the radiology staffing shortage

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.